The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Imagem de Miniatura
Arquivos
art_SANTHIAGO_Validation_of_the_Percent_Tissue_Altered_as_a_2019.PDF (298.63 KB)
Citações na Scopus
100
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
FRUCHART, Jean-Charles
AGUILAR-SALINAS, Carlos
AIKAWA, Masanori
RASADI, Khalid Al
AMARENCO, Pierre
BARTER, Philip J.
CESKA, Richard
CORSINI, Alberto
DESPRES, Jean-Pierre
Citação
CARDIOVASCULAR DIABETOLOGY, v.18, article ID 71, 20p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARM) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARM agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARM agonist safely reduces residual cardiovascular risk.
Palavras-chave
Residual cardiovascular risk, Visceral obesity, Diabetes, Atherogenic dyslipidemia, Triglycerides, Remnant cholesterol, Selective peroxisome proliferator-activated receptor alpha modulator, SPPARMalpha, Pemafibrate (K-877), Inflammation, PROMINENT
URI
https://observatorio.fm.usp.br/handle/OPI/32451
Referências
  1. Adams LA, 2017, GUT, V66, P1138, DOI 10.1136/gutjnl-2017-313884
  2. Adiels M, 2006, DIABETOLOGIA, V49, P755, DOI 10.1007/s00125-005-0125-z
  3. Anand SS, 2018, LANCET, V391, P219, DOI 10.1016/S0140-6736(17)32409-1
  4. Angajala A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01605
  5. [Anonymous], 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
  6. Arai H, 2018, J ATHEROSCLER THROMB, V25, P521, DOI 10.5551/jat.44412
  7. Arai H, 2017, ATHEROSCLEROSIS, V261, P144, DOI 10.1016/j.atherosclerosis.2017.03.032
  8. Araki E, 2018, DIABETES CARE, V41, P538, DOI 10.2337/dc17-1589
  9. Araki M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072148
  10. Augustus A, 2004, J BIOL CHEM, V279, P25050, DOI 10.1074/jbc.M401028200
  11. Austin MA, 2000, CIRCULATION, V101, P2777, DOI 10.1161/01.CIR.101.24.2777
  12. Bansal S, 2007, JAMA-J AM MED ASSOC, V298, P309, DOI 10.1001/jama.298.3.309
  13. Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
  14. Bennett JE, 2018, LANCET, V392, P1072, DOI 10.1016/S0140-6736(18)31992-5
  15. Besseiche A, 2015, DIABETES METAB, V41, P347, DOI 10.1016/j.diabet.2015.02.002
  16. Bhatt DL, 2019, NEW ENGL J MED, V380, P11, DOI 10.1056/NEJMoa1812792
  17. Boden WE, 2011, NEW ENGL J MED, V365, P2255, DOI 10.1056/NEJMoa1107579
  18. Bonaca MP, 2018, CIRCULATION, V137, P338, DOI 10.1161/CIRCULATIONAHA.117.032235
  19. Boren J, 2015, ARTERIOSCL THROM VAS, V35, P2218, DOI 10.1161/ATVBAHA.115.305614
  20. Bougarne N, 2018, ENDOCR REV, V39, P760, DOI 10.1210/er.2018-00064
  21. Brocker CN, 2018, J LIPID RES, V59, P2140, DOI 10.1194/jlr.M088419
  22. Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673
  23. Brunzell JD, 2008, DIABETES CARE, V31, P811, DOI 10.2337/dc08-9018
  24. Catapano AL, 2016, EUR HEART J, V37, P2999, DOI 10.1093/eurheartj/ehw272
  25. Chapman MJ, 2011, EUR HEART J, V32, P1345, DOI 10.1093/eurheartj/ehr112
  26. Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
  27. Crosby J, 2014, NEW ENGL J MED, V371, P22, DOI 10.1056/NEJMoa1307095
  28. Davidson MH, 2006, EXPERT OPIN DRUG SAF, V5, P145, DOI 10.1517/14740338.5.1.145
  29. Davis TME, 2011, DIABETOLOGIA, V54, P280, DOI 10.1007/s00125-010-1951-1
  30. Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048
  31. Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0
  32. Dewey FF, 2016, NEW ENGL J MED, V374, P1123, DOI 10.1056/NEJMoa1510926
  33. Doycheva I, 2018, J CLIN GASTROENTEROL, V52, P339, DOI 10.1097/MCG.0000000000000925
  34. Elam MB, 2017, JAMA CARDIOL, V2, P370, DOI 10.1001/jamacardio.2016.4828
  35. Faergeman O, 2009, AM J CARDIOL, V104, P459, DOI 10.1016/j.amjcard.2009.04.008
  36. Fan WJ, 2019, J CLIN LIPIDOL, V13, P100, DOI 10.1016/j.jacl.2018.11.008
  37. Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144
  38. Fruchart JC, 2017, CARDIOVASC DIABETOL, V16, DOI 10.1186/s12933-017-0602-y
  39. Fruchart JC, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-82
  40. Fruchart JC, 2009, ATHEROSCLEROSIS, V205, P1, DOI 10.1016/j.atherosclerosis.2009.03.008
  41. Fruchart JC, 2008, AM J CARDIOL, V102, p1K, DOI [10.1016/j.amjcard.2008.10.002, 10.1016/S0002-9149(08)01833-X]
  42. Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282
  43. Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173
  44. Grundy Scott M, 2018, J Am Coll Cardiol, DOI 10.1016/j.jacc.2018.11.003
  45. Halcox JP, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0591-5
  46. Handelsman Y, 2015, ENDOCR PRACT, V21, P1, DOI [10.4158/EP15672.GLSUPPL, 10.4158/EP15672.GL]
  47. Haynes R, 2013, EUR HEART J, V34, P1279, DOI 10.1093/eurheartj/eht055
  48. Hedrington MS, 2018, EXPERT OPIN DRUG MET, V14, P671, DOI 10.1080/17425255.2018.1483337
  49. Hennuyer N, 2016, ATHEROSCLEROSIS, V249, P200, DOI 10.1016/j.atherosclerosis.2016.03.003
  50. Honda Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep42477
  51. Hounslow N, 2018, ATHEROSCLEROSIS SUPP, V32, P155
  52. Ishibashi S, 2018, J CLIN LIPIDOL, V12, P173, DOI 10.1016/j.jacl.2017.10.006
  53. Ishibashi S, 2016, ATHEROSCLEROSIS, V249, P36, DOI 10.1016/j.atherosclerosis.2016.02.029
  54. Iwata H, 2014, CIRC RES, V115, pE90
  55. Jepsen AMK, 2016, CLIN CHEM, V62, P593, DOI 10.1373/clinchem.2015.253757
  56. Jernberg T, 2015, EUR HEART J, V36, P1163, DOI 10.1093/eurheartj/ehu505
  57. Jorgensen AB, 2014, NEW ENGL J MED, V371, P32, DOI 10.1056/NEJMoa1308027
  58. Joseph P, 2017, CIRC RES, V121, P677, DOI 10.1161/CIRCRESAHA.117.308903
  59. Juntti-Berggren L, 2017, CURR OPIN LIPIDOL, V28, P27, DOI 10.1097/MOL.0000000000000372
  60. KASTELEIN JJP, 2015, EUR HEART J S1, V36, P1048
  61. Kastelein JJP, 2008, CIRCULATION, V117, P3002, DOI 10.1161/CIRCULATIONAHA.107.713438
  62. Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
  63. Kersten S, 2017, NAT REV ENDOCRINOL, V13, P731, DOI 10.1038/nrendo.2017.119
  64. Kharitonenkov A, 2015, TRENDS ENDOCRIN MET, V26, P608, DOI 10.1016/j.tem.2015.09.007
  65. Khera AV, 2017, JAMA-J AM MED ASSOC, V317, P937, DOI 10.1001/jama.2017.0972
  66. Klempfner R, 2016, CIRC-CARDIOVASC QUAL, V9, P100, DOI 10.1161/CIRCOUTCOMES.115.002104
  67. Krishnan V, 2000, Vitam Horm, V60, P123, DOI 10.1016/S0083-6729(00)60018-3
  68. Lauridsen BK, 2018, EUR HEART J, V39, P385, DOI 10.1093/eurheartj/ehx662
  69. Lewis JS, 2005, MUTAT RES-FUND MOL M, V591, P247, DOI 10.1016/j.mrfmmm.2005.02.028
  70. Libby P, 2015, EUR HEART J, V36, P774, DOI 10.1093/eurheartj/ehu500
  71. Lincoff AM, 2017, NEW ENGL J MED, V376, P1933, DOI 10.1056/NEJMoa1609581
  72. Madsen CM, 2019, CLIN CHEM, V65, P644, DOI [10.1373/clinchem.2018.294926, 10.1373/clinchem.2018.299636]
  73. Maki T, 2017, METABOLISM, V71, P33, DOI 10.1016/j.metabol.2017.02.013
  74. Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125
  75. Marx N, 2004, CIRC RES, V94, P1168, DOI 10.1161/01.RES.0000127122.22685.0A
  76. Marx N, 2001, CIRCULATION, V103, P213
  77. Matsuba I, 2018, J DIABETES INVEST, V9, P1323, DOI 10.1111/jdi.12845
  78. Miller M, 2008, J AM COLL CARDIOL, V51, P724, DOI 10.1016/j.jacc.2007.10.038
  79. Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726
  80. Moens SJB, 2017, ARTERIOSCL THROM VAS, V37, P969, DOI 10.1161/ATVBAHA.116.308834
  81. Mychaleckyj JC, 2012, DIABETES CARE, V35, P1008, DOI 10.2337/dc11-1811
  82. Neve BP, 2001, CIRCULATION, V103, P207
  83. Nichols GA, 2019, DIABETES OBES METAB, V21, P366, DOI 10.1111/dom.13537
  84. Nilsson SK, 2011, ATHEROSCLEROSIS, V219, P15, DOI 10.1016/j.atherosclerosis.2011.07.019
  85. Nissen SE, 2007, JAMA-J AM MED ASSOC, V297, P1362, DOI 10.1001/jama.297.12.1362
  86. Nordestgaard BG, 1997, CIRCULATION, V96, P1737, DOI 10.1161/01.CIR.96.6.1737
  87. NORDESTGAARD BG, 1995, ARTERIOSCL THROM VAS, V15, P534, DOI 10.1161/01.ATV.15.4.534
  88. NORDESTGAARD BG, 1988, ARTERIOSCLEROSIS, V8, P421, DOI 10.1161/01.ATV.8.4.421
  89. Nordestgaard BG, 2007, JAMA-J AM MED ASSOC, V298, P299, DOI 10.1001/jama.298.3.299
  90. Nordestgaard BG, 2016, EUR HEART J, V37, P1944, DOI 10.1093/eurheartj/ehw152
  91. Nordestgaard BG, 2014, LANCET, V384, P626, DOI 10.1016/S0140-6736(14)61177-6
  92. Nussbaumerova B, 2014, COR VASA, V56, pE98, DOI 10.1016/j.crvasa.2014.02.002
  93. Olubamwo OO, 2018, EUR J GASTROEN HEPAT, V30, P1047, DOI 10.1097/MEG.0000000000001183
  94. Ong KL, 2017, CLIN CHEM, V63, P1261, DOI 10.1373/clinchem.2016.270876
  95. Patel KV, 2018, CIRCULATION, V137, P2551, DOI 10.1161/CIRCULATIONAHA.118.035289
  96. Pennacchio LA, 2003, ARTERIOSCL THROM VAS, V23, P529, DOI 10.1161/01.ATV.0000054194.78240.45
  97. Piche ME, 2018, PROG CARDIOVASC DIS, V61, P103, DOI 10.1016/j.pcad.2018.06.004
  98. Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI [10.1093/eurheartj/ehw106, 10.1016/j.rec.2016.09.009]
  99. Ponte-Negretti CI, 2017, INT J CARDIOL, V243, P516, DOI 10.1016/j.ijcard.2017.05.059
  100. Pradhan AD, 2018, AM HEART J, V206, P80, DOI 10.1016/j.ahj.2018.09.011
  101. Puri R, 2016, ARTERIOSCL THROM VAS, V36, P2220, DOI 10.1161/ATVBAHA.116.307601
  102. Raza-Iqbal S, 2015, J ATHEROSCLER THROMB, V22, P754, DOI 10.5551/jat.28720
  103. Reiner Z, 2013, ATHEROSCLEROSIS, V231, P300, DOI 10.1016/j.atherosclerosis.2013.09.020
  104. Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
  105. Sabatine MS, 2017, LANCET DIABETES ENDO, V5, P941, DOI 10.1016/S2213-8587(17)30313-3
  106. Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI 10.1056/NEJMoa1615664
  107. Sacks FM, 2000, CIRCULATION, V102, P1886, DOI 10.1161/01.CIR.102.16.1886
  108. Sacks FM, 2014, CIRCULATION, V129, P999, DOI 10.1161/CIRCULATIONAHA.113.002529
  109. Saely CH, 2010, NEW ENGL J MED, V363, P692, DOI 10.1056/NEJMc1006407
  110. Sairyo M, 2018, J ATHEROSCLER THROMB, V25, P142, DOI 10.5551/jat.39693
  111. Santos RD, 2019, ATHEROSCLEROSIS, V282, P110, DOI 10.1016/j.atherosclerosis.2019.01.029
  112. SASAKI Y, 2018, DIABETES S1, V67, DOI 10.2337/db18-1153-p
  113. Schlein C, 2016, CELL METAB, V23, P441, DOI 10.1016/j.cmet.2016.01.006
  114. Schwartz GG, 2018, NEW ENGL J MED, V379, P2097, DOI 10.1056/NEJMoa1801174
  115. Schwartz GG, 2015, J AM COLL CARDIOL, V65, P2267, DOI 10.1016/j.jacc.2015.03.544
  116. Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
  117. Shi L, 2015, CURR OPIN CELL BIOL, V33, P125, DOI 10.1016/j.ceb.2015.02.003
  118. Staels B, 2008, NAT CLIN PRACT CARD, V5, P542, DOI 10.1038/ncpcardio1278
  119. STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719
  120. Stitziel NO, 2017, J AM COLL CARDIOL, V69, P2054, DOI 10.1016/j.jacc.2017.02.030
  121. Stitziel NO, 2016, NEW ENGL J MED, V374, P1134, DOI 10.1056/NEJMoa1507652
  122. Takei K, 2017, J DIABETES INVEST, V8, P446, DOI 10.1111/jdi.12621
  123. Takei K, 2017, J PHARMACOL SCI, V133, P214, DOI 10.1016/j.jphs.2017.02.003
  124. Taskinen MR, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0614-1
  125. Aung T, 2018, JAMA CARDIOL, V3, P225, DOI 10.1001/jamacardio.2017.5205
  126. Tikka A, 2016, ENDOCRINE, V52, P187, DOI 10.1007/s12020-015-0838-9
  127. Torra IP, 2002, MOL ENDOCRINOL, V16, P1013
  128. Toth PP, 2018, J AM HEART ASSOC, V7, DOI [10.1161/JAHA.118.008740, 10.1161/jaha.118.008740]
  129. Toth PP, 2012, J CLIN LIPIDOL, V6, P325, DOI 10.1016/j.jacl.2012.05.002
  130. TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x
  131. Vallejo-Vaz AJ, 2018, CIRCULATION, V138, P770, DOI 10.1161/CIRCULATIONAHA.117.032318
  132. Varbo A, 2018, CLIN CHEM, V64, P219, DOI 10.1373/clinchem.2017.279463
  133. Varbo A, 2015, CLIN CHEM, V61, P533, DOI 10.1373/clinchem.2014.234146
  134. Varbo A, 2014, PHARMACOL THERAPEUT, V141, P358, DOI 10.1016/j.pharmthera.2013.11.008
  135. Varbo A, 2013, J AM COLL CARDIOL, V61, P427, DOI 10.1016/j.jacc.2012.08.1026
  136. Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2
  137. Wahli W, 2012, TRENDS ENDOCRIN MET, V23, P351, DOI 10.1016/j.tem.2012.05.001
  138. World Health Organization, OBS OV
  139. Yamamoto Y, 2018, BIOCHEM BIOPH RES CO, V499, P239, DOI 10.1016/j.bbrc.2018.03.135
  140. Yamashita S, 2018, J CLIN LIPIDOL, V12, P1267, DOI 10.1016/j.jacl.2018.06.010
  141. Yamazaki Y, 2007, BIOORG MED CHEM LETT, V17, P4689, DOI 10.1016/j.bmcl.2007.05.066
  142. Yokote K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030706
  143. Yokote K, 2018, ATHEROSCLEROSIS SUPP, V32, P155, DOI 10.1016/j.atherosclerosissup.2018.04.471
  144. Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3
  145. Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431
  146. Zheng CY, 2013, EUR HEART J, V34, P615, DOI 10.1093/eurheartj/ehs271
  147. ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473
  148. Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - ODS/03